The study aims at evaluating the efficacy of combined administration of imiquimod 5% crème and human papillomavirus (HPV) quadrivalent recombinant vaccine in order to achieve a long‐term clinical remission in patients with chronic HPV infection manifested in condyloma accuminata (CA) of the anogenital area. The study enrolled 36 subjects aged 26.4 (4.1) years (including 22 men) with one to five condyloma accuminata of the anogenital area. Study participants were vaccinated with human papillomavirus quadrivalent recombinant vaccine using a 0–2–6‐month regimen with concomitant administration of imiquimod 5% crème applied three times per week for not more than 16 weeks. Patients were monitored over 2 years. Complete disappearance of condyloma accuminata was observed in 34 out of 36 subjects (94.4%) after 1 year from the start of treatment. Two patients still having condyloma accuminata of the anogenital area after 1 year of combination treatment underwent a successful course of treatment with Solcoderm (one patient for 1 year 3 months and the other for 1 year 4 months), which resulted in complete disappearance of condyloma accuminata. Within 2‐year period, no recurrence of condyloma accuminata of the anogenital area has been observed.
Part of the book: Vaccines